Abstract
Mandated by the Political Declaration of the High-level Meeting on Antimicrobial Resistance at the 79th Session of the UN General Assembly in September 2024, the development of another key component to improve and accelerate global steering of the AMR response is currently underway: the Independent Panel on Evidence for Action against AMR (IPEA). The landscape of global antimicrobial resistance (AMR) governance has gradually evolved over the past few years, with the creation of key mechanisms including: the establishment of the Global Leaders Group in 2020, providing advocacy and advisory functions the Tripartite becoming the Quadripartite in 2022, a joint initiative by FAO, UNEP, WHO and WOAH addressing AMR in a more coordinated One Health approach in addition to the Multi-stakeholder Partnership Platform (MSPP) established in 2023 as a volutary collaborative platform. Mandated by the Political Declaration of the High-level Meeting on AMR at the 79th Session of the UN General Assembly in September 2024, the development of another key component to improve and accelerate global steering of the AMR response is currently underway: the Independent Panel on Evidence for Action against AMR (IPEA). IPEA: A foundation for evidence-based action The proposed objective of the IPEA according to the zero draft is to assess and facilitate the generation and use of multi-sectoral, policy-relevant scientific evidence to support Member States at all levels in their efforts to tackle antimicrobial resistance (AMR) applying a One Health approach, making use of existing resources and avoiding duplication of ongoing efforts"."